Heart failure
Imbria Pharmaceuticals Clears Safety Hurdles in Phase 2 Heart Failure Trial, Paving the Way for Promising Late-Stage Development
Imbria Pharmaceuticals has achieved positive results in a phase 2 trial for its heart failure medication. The Boston-based biotech, in ...
BioCardia’s cell therapy fails to improve heart failure outcomes in Phase 3 trial
BioCardia’s attempts to revive its paused phase 3 heart failure trial have hit a major setback, as results fail to ...
Bayer launches new trials for Kerendia, a potential blockbuster for heart failure
Two summers ago, Bayer introduced Kerendia (finerenone) as a treatment for chronic kidney disease (CKD) linked to type 2 diabetes. ...
AstraZeneca’s Farxiga confident of its edge over Novo’s Wegovy in heart failure market
Novo Nordisk’s semaglutide and AstraZeneca’s Farxiga assuming the roles of formidable contenders. The arena is no longer confined to blood ...
Unveiling the Intricate Symphony: AstraZeneca’s Farxiga at the Heart of Cardiorenal Insights
In the heart of Amsterdam, amidst the captivating backdrop of the European Society of Cardiology (ESC) scientific sessions, AstraZeneca wielded ...
Novo Nordisk’s Semaglutide Triumphs Again: A Heartfelt Victory in the Battle Against Heart Failure
In a remarkable turn of events, the pharmaceutical landscape witnesses Novo Nordisk’s semaglutide, a true star in its arsenal, claiming ...
Astellas and Eko Partner for Heart Failure Digital Therapeutics with Eko CORE 500™ Stethoscope
Source – Astellas Pharma Astellas has obtained the licensing rights to a smart stethoscope device developed by Eko Health, with ...
